Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in [...] Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trialcurechm2019-08-28T17:45:45-05:00
